Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage.
James W Anderson
Index: Expert Opin. Pharmacother. 8(11) , 1733-42, (2007)
Full Text: HTML
Abstract
Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss with diet and orlistat 60 mg averages ~5% of initial body weight. The 60-mg dose is better tolerated than the 120-mg dose and the gastrointestinal side effects are minimal when individuals consume < 30% of their energy from fat. In addition to facilitating modest weight loss, orlistat use decreases serum LDL-cholesterol values by ~10%. When taken three times daily before meals, orlistat 60 mg modifies lifestyle behavior, encourages lower fat-consumption and sets the stage for other healthy lifestyle changes.
Related Compounds
Related Articles:
Orlistat and calcium oxalate crystalluria: an association that needs consideration.
2010-01-01
[Ren. Fail. 32(8) , 1019-21, (2010)]
Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
2013-01-01
[J. La. State Med. Soc. 165(5) , 283-5, (2013)]
2015-04-01
[Food Funct. 6 , 1319-30, (2015)]
2013-09-01
[Minerva Endocrinol. 38(3) , 245-54, (2013)]
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
2005-11-01
[Expert Opin. Pharmacother. 6(14) , 2483-91, (2005)]